Core Viewpoint - The legal opinion from Beijing Tianyuan Law Firm confirms that Shanghai Meinong Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, adhering to relevant laws and regulations [1][2][4]. Group 1: Eligibility for Stock Incentive Plan - Shanghai Meinong Biotechnology has met the conditions for implementing a stock incentive plan as per the Management Measures [2][4]. - The company is a legally established and effectively existing joint-stock company, with no circumstances that would prevent it from implementing the stock incentive plan [3][4]. Group 2: Legality and Compliance of the Incentive Plan - The incentive plan has been reviewed and found to comply with the relevant provisions of the Management Measures and Listing Rules [5][8]. - The plan includes specific provisions regarding the types, sources, and quantities of restricted stock, which align with regulatory requirements [6][7]. Group 3: Legal Procedures Followed - The company has followed the necessary legal procedures, including meetings of the independent directors and the remuneration and assessment committee, to approve the incentive plan [8][10]. - The company will disclose the names and positions of the incentive plan participants prior to the shareholders' meeting, ensuring transparency [9][11]. Group 4: Financial Support and Impact on Shareholders - The company has committed not to provide any financial assistance to the incentive plan participants for acquiring restricted stock, in compliance with regulations [12]. - The incentive plan is not expected to harm the interests of the company or its shareholders, as confirmed by the remuneration and assessment committee [12][13]. Group 5: Conclusion - The legal opinion concludes that the incentive plan is compliant with the Management Measures and requires approval from the shareholders' meeting to be implemented [14].
美农生物: 北京市天元律师事务所关于上海美农生物科技股份有限公司2025年限制性股票激励计划的法律意见